Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 83 Thoracic 49 Genitourinary 34 Head & Neck 26 Dermatologic 20 Breast 15 Other solid neoplasm 14 Gynecologic 12 Tumor-Agnostic 3 Sarcoma 3 Lymphoid 3 Endocrine 3 Plasma cell 1 Other neoplasm 1 Other hematologic neoplasm 1 NET 1 CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 48 Everolimus 40 Magnetic Resonance Spectroscopy 21 lanreotide 17 Temozolomide 17 gallium Ga 68 dotatate 15 Octreotide 15 pembrolizumab 13 Nivolumab 13 surufatinib 12 Capecitabine 12 cabozantinib 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 Sunitinib 10 pasireotide 9 Specimen Handling 9 Positron Emission Tomography Computed Tomography 9 Lutetium-177 9 3-Iodobenzylguanidine 9 Ga(III)-DOTATOC 8 Carboplatin 8 telotristat ethyl 6 copper dotatate CU-64 6 amino-acid, glucose, and electrolyte solution 6 Somatostatin 6 Ipilimumab 6 Fluorodeoxyglucose F18 6 Etoposide 6 Cisplatin 6 90Y-octreotide, DOTA-Tyr(3)- 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

tremelimumab × NET × Clear all

NCT03095274 2025-01-09

DUNE

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

126 enrolled 18 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡